Prospective evaluation of twice-daily cefotaxime in the treatment of hospitalized patients with severe infections.
Cefotaxime 2 g every 12 h was administered to adults with severe nosocomial pneumonia in a prospective noncomparative study. The results confirmed that this regimen is adequate and appropriate therapy for nosocomial pneumonia, with the combination of cefotaxime and an aminoglycoside reserved for cases where multiresistant, Gram-negative bacterial infections are strongly suspected.
Keller
C
C
Department of Lung and Bronchial Diseases, Nordwestkrankenhaus, Frankfurt, Germany.
D000328:Adult; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002439:Cefotaxime / Q000008:administration & dosage / Q000627:therapeutic use*; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D004334:Drug Administration Schedule; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D011446:Prospective Studies; D016896:Treatment Outcome
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002439:Cefotaxime